🔗 Share this article

As the United States continues making sweeping revisions to its vaccine guidelines, a particular individual appears unexpectedly: Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by casting doubt on coronavirus shots throughout the pandemic and has concentrated on possible fatalities after Covid immunization in her brief time at the FDA.

Scheduled Changes to Childhood Immunization Program

Public health authorities were set to announce radical revisions to the childhood vaccine schedule recently, synchronizing the US with Denmark’s national calendar, according to reports – a substantial departure that would put the US at odds with many the world with no evidence for benefit. The planned update has been delayed until the new year.

Instead of the top vaccines chief, Dr. Høeg is scheduled to speak at the gathering. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth person to head the office this year.

A Shift at the FDA

Høeg's temporary position might represent a tighter collaboration between the drug and vaccine centers as Høeg and Prasad solidify control at the regulatory agency – and it suggests a renewed priority upon reevaluating already-approved immunizations at the FDA.

The new acting director has often pushed for discontinuing certain childhood shot schedules in the US to become more similar to Denmark's approach, a country with universal health coverage and a citizenry about the size of the state of Wisconsin.

In her initial public appearances, she has continued to focus on immunizations – typically the purview of Prasad, director of the FDA’s vaccine center – rather than medication approval.

Questions Over Expertise

Høeg has no apparent track record in drug development, regulation or leadership, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the commissioner and CBER since March.

“It seems she lacks to have the necessary background” for overseeing the drug-regulation department, stated a neurologist and psychiatrist. “She has not conducted a clinical trial. She lacks experience in managing a major agency. She is not an expert in pharmaceutical oversight.”

Previous directors of CBER would “understand legal statutes and the research of medication creation”, noted Janet Woodcock. “Clearly, she lacks the kind of background that previous people who ran the center have had.”

This division has an vast workload at the agency, Woodcock emphasized.

“Many people just pays attention on the new drug program, but the generic program authorizes numerous generic drugs. There is also a biosimilars program, OTC medication office and so forth, and all of those must be managed,” she said. “The area you neglect, that is precisely what that I always told people is going to bite you.”

There is also, a substantial administrative aspect to the role, which manages over 5,000 personnel. “It’s a massive administrative position, if you execute it properly,” she said.

Official Statement and Contentious Policies

Regarding questions about Høeg’s credentials and whether this selection indicates increased cooperation among regulatory chiefs on vaccines, a press secretary said that the “inquiries stem from flawed presumptions”.

“This background matches the responsibilities of her role,” the official said, noting the time Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and vaccine surveillance”.

As acting director, Høeg takes over the agency head's controversial priority voucher program, a disputed rapid drug-approval program that allegedly worried her predecessors. “By what process are these medications being picked for this voucher program? Who is making the calls?” Howard asked. “There is a lot of confidentiality happening at the agency right now.”

Broadly speaking, he remarked, “the FDA appears to be shifting towards more relaxed rules of most medications, aside from vaccines.”

Documented History on Vaccines

With vaccines, Dr. Høeg has a more documented, if concerning, past, some experts observe. She published a study using unverified volunteer-provided data to assess the incidence of myocarditis after Covid immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to imply COVID-19 vaccines are more dangerous than they are.

Included in her “desired changes” for the new administration featured changing regulations for recently developed shots and halting “optional” vaccines, she remarked following the vote on a audio program. At the agency, Høeg has according to sources suggested preventing adolescent males from receiving COVID-19 vaccines.

“She is an complete true believer who commences with her beliefs and works backwards to retrofit the evidence in a highly disingenuous, dishonest way,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with other skeptics, {like|